About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Millennium Pharmaceuticals Inc. v. Dr. Reddys Laboratories, Ltd. et al.
1:15-cv-00539; filed June 25, 2015 in the District Court of Delaware

• Plaintiff:  Millennium Pharmaceuticals Inc.
• Defendants:  Dr. Reddys Laboratories, Ltd.; Dr. Reddys Laboratories, Inc.

Millennium Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd. et al.
1:15-cv-0053940; filed June 25, 2015 in the District Court of Delaware

• Plaintiff:  Millennium Pharmaceuticals Inc.
• Defendants:  Sun Pharmaceutical Industries Ltd.; Sun Pharma Global FZE; Sun Pharmaceutical Industries Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 6,713,446 ("Formulation of Boronic Acid Compounds," issued March 30, 2004) and 6,958,319 (same title, issued October 25, 2005), licensed exclusively to Millennium, following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Millenium's Velcade® (bortezomib, used to treat multiple myeloma).  View the Dr. Reddy's complaint here.

Novartis Pharmaceuticals Corp. v. Aurobindo Pharma Ltd. et al.
2:15-cv-04427; filed June 25, 2015 in the District Court of New Jersey

• Plaintiff:  Novartis Pharmaceuticals Corp.
• Defendants:  Aurobindo Pharma Ltd.; Aurobindo Pharma USA, Inc.

Infringement of U.S. Patent No. 8,324,189 ("Use of Zolendronate for the Manufacture of a Medicament for the Treatment of Bone Metabolism Diseases," issued December 4, 2012) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Novartis' Zometa® (zoledronic acid, used for the prevention of skeletal-related complications associated with cancer).  View the complaint here.

Cephalon, Inc. v. Fresenius Kabi USA, LLC
1:15-cv-00536; filed June 24, 2015 in the District Court of Delaware

Infringement of U.S. Patent No. 8,344,006 ("Liquid Formulations of Bendamustine," issued on January 1, 2013) following a Paragraph IV certification as part of Fresenius' filing of an ANDA to manufacture a generic version of Cephalon's Treanda® (bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma).  View the complaint here.

Ferring B.V. et al. v. Actavis, Inc. et al.
Filed June 23, 2015 in the District Court of New Jersey

• Plaintiffs:  Ferring B.V.; Ferring International Center S.A.; Ferring Pharmaceuticals Inc.
• Defendants:  Actavis, Inc.; Watson Laboratories, Inc.; Andrx Corp.; Watson Laboratories, Inc. – Florida; Watson Pharama, Inc.

Infringement of U.S. Patent No. 9,060,939 ("Tranexamic Acid Formulations," issued June 23, 2015) following in conjunction with Watson's filing of an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic acid, used to treat heavy menstrual bleeding).  View the complaint here.